<DOC>
	<DOCNO>NCT00107341</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together paclitaxel carboplatin may kill tumor cell . PURPOSE : This phase II trial study well give bortezomib together paclitaxel carboplatin work treat patient unresectable , metastatic cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>Bortezomib , Paclitaxel , Carboplatin Treating Patients With Unresectable , Metastatic Cancer Esophagus Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine confirm tumor response rate patient unresectable , metastatic adenocarcinoma esophagus , gastroesophageal junction , gastric cardia treat bortezomib , paclitaxel , carboplatin . Secondary - Determine time tumor progression , overall survival , duration response patient treat regimen . - Determine adverse event patient treat regimen . OUTLINE : This multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 paclitaxel IV 3 hour carboplatin IV 30 minute day 2 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month disease progression every 6 month 3 year . PROJECTED ACCRUAL : A total 25-60 patient accrue study within 17 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma 1 follow site : Esophagus Gastroesophageal junction Gastric cardia No great 2 cm gastroesophageal junction stomach Unresectable , metastatic disease Not candidate potentially curative therapy AND reasonable potentially curative conventional therapy exist At least 1 measurable lesion ≥ 2.0 cm conventional technique OR ≥ 1.0 cm spiral CT scan No known CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN Renal Creatinine ≤ 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No peripheral neuropathy ≥ grade 2 No uncontrolled infection No chronic debilitate disease No prior allergic reaction carboplatin paclitaxel No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy recurrent metastatic disease No prior biologic therapy recurrent metastatic disease No concurrent prophylactic colonystimulating factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy No prior chemotherapy recurrent metastatic disease Prior chemotherapy neoadjuvant adjuvant setting ( complete resection original tumor ) allow Prior combination chemotherapy radiotherapy allow provided patient achieve complete response AND last dose combination therapy administer ≥ 6 month ago Endocrine therapy Not specify Radiotherapy See Chemotherapy No prior radiotherapy recurrent metastatic disease Prior radiotherapy neoadjuvant adjuvant setting ( complete resection original tumor ) allow No prior radiotherapy &gt; 25 % bone marrow locally advance disease More 4 week since prior radiotherapy Surgery More 4 week since prior open abdominal exploration ( e.g. , laparotomy ) More 2 week since prior minimally invasive procedure ( e.g. , laparoscopy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>